You are here

AstraZeneca slumps on report CEO is heading to Teva

BT_20170714_PASCAL_2981815.jpg
Moving to a generic drugmaker, albeit the world's largest, would be a big change in direction for French-born Mr Soriot, 58.

London

SHARES in AstraZeneca fell more than 5 per cent on Thursday after the company declined to deny a media report that chief executive Pascal Soriot was about to defect to Israel-based Teva Pharmaceutical Industries.

Mr Soriot, who has led the Anglo- Swedish company since 2012,

sentifi.com

Market voices on:

Powered by GET.comGetCom